Key parameters of measles virus production for oncolytic virotherapy


Show simple item record Weiss, K. Salzig, D. Mühlebach, M. D. Cichutek, K. Pörtner, R. Czermak, Peter 2012-07-11T22:12:09Z 2012-07-11T22:12:09Z 2012-07-11
dc.description.abstract Attenuated measles virus has revealed selective tumor cell killing and is currently tested in clinical trials for the therapy of cancer patients. The amount of infectious particles per dose needed for oncolytic therapy can be more than a million times higher compared to vaccination. This requires highly effective production processes which guarantee the measles virus quantities needed for its use in cancer therapy. Referring to measles virus production itself, several factors are influencing process parameters and subsequent virus yields. These factors are medium optimization, feeding of nutrients, an optimal multiplicity of infection, localization of produced virus particles, temperature sensitivity and time of harvest. This review summarizes the available data concerning measles virus production in cell culture and factors influencing the virus yield. en_US
dc.relation.uri en_US
dc.subject Measles virus en_US
dc.subject Subacute sclerosing panencephalitis en_US
dc.subject Major complement protein en_US
dc.subject Cytopathic effect en_US
dc.title Key parameters of measles virus production for oncolytic virotherapy en_US
dc.type Article (publisher version) en_US 2012 en_US
dc.citation.doi doi:10.3844/ajbbsp.2012.81.98 en_US
dc.citation.epage 98 en_US
dc.citation.issue 2 en_US
dc.citation.jtitle American Journal of Biochemistry and Biotechnology en_US
dc.citation.spage 81 en_US
dc.citation.volume 8 en_US
dc.contributor.authoreid pczermak en_US

Files in this item

Files Size Format View

This item appears in the following Collection(s)

Show simple item record